Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingBlue Cross Blue Shield - Kansas PET Coverage Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedBlue Cross Blue Shield - KansasPolicy N/A

    PET scanning for genitourinary cancers

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing use of PET and PET/CT (various radiotracers) for diagnosis, staging, restaging, and surveillance of genitourinary malignancies for Blue Cross Blue Shield of Kansas members.

    Policy Summary
    PayerBlue Cross Blue Shield - Kansas
    PolicyPET scanning for genitourinary cancers
    Policy CodePolicy N/A
    Change TypeRevisions to PET languageadded HCPCS code A9616
    Effective DateJan 13, 2026
    Last ReviewJan 13, 2026
    Next Review DateJan 13, 2026
    Key ActionRequest prior authorization and document that PET results will influence treatment decisions and align indication with guideline-supported criteria (e.g., NCCN/SNMMI).
    SourceLink
    POLICY UPDATE CHANGES

    Changed A1, B1, C2, D1, E1: From PET to FDG-PET/CT.

    Added new HCPCS code A9616 effective 10-01-2025.

    Updated Description, Policy, Policy Guidelines, Rationale, and Reference sections on 01-13-2026.

    7distinct named genitourinary cancer sections
    multiplenew/updated HCPCS radiopharmaceutical codes listed
    Surveillance excludedsurveillance excluded (>6 mo / 12 mo lymphoma)
    89%pooled sensitivity for PSMA PET (diagnosis)
    87%FDG-PET/CT for penile cancer pooled sensitivity

    Coverage Criteria for PET/PET-CT — Genitourinary Cancers

    A. Bladder Cancer

    Bladder cancer coverage statements

    Bladder cancer - muscle invasive: FDG-PET/CT may be considered medically necessary for staging or restaging of muscle-invasive bladder cancer when CT or MRI are not indicated or remain inconclusive for distant metastasis.stage >= cT2
    Bladder cancer - non-muscle invasive: PET scanning is experimental/investigational for bladder tumors that have not invaded the muscle (stage < cT2).stage < cT2

    B. Penile Cancer

    Penile cancer coverage statements

    Policy Summary
    PayerBlue Cross Blue Shield - Kansas
    PolicyPET scanning for genitourinary cancers
    Policy CodePolicy N/A
    Change TypeRevisions to PET languageadded HCPCS code A9616
    Effective DateJan 13, 2026
    Last ReviewJan 13, 2026
    Next Review DateJan 13, 2026
    Key ActionRequest prior authorization and document that PET results will influence treatment decisions and align indication with guideline-supported criteria (e.g., NCCN/SNMMI).
    SourceLink
    On This Page
    Coverage Criteria for PET/PET-CT — Genitourinary CancersSpecific Covered IndicationsProcedure and Radiopharmaceutical CodesPrior Authorization, Documentation, and Ordering GuidanceImaging Protocol and Contrast ConsiderationsUses Considered Experimental/Investigational or Not CoveredKey Definitions and TermsPrior Authorization ExpectationsBackground — PET/PET-CT and RadiotracersFrequency Limits and Related NotesRationale, Evidence Summary, and References
    Penile cancer - inguinal node positive:
    FDG-PET/CT may be considered medically necessary for staging and restaging in individuals with suspected inguinal lymph node positive disease.
    inguinal lymph node positive suspected
    Penile cancer - other: PET scanning is experimental/investigational in all other aspects of managing penile cancer.other indications

    C. Prostate Cancer

    Prostate cancer coverage statements

    Prostate - choline/fluciclovine recurrence: PET with carbon-11 choline and F-18 fluciclovine may be considered medically necessary for evaluating suspected or biochemically recurrent prostate cancer after primary treatment to detect small-volume disease in soft tissues.biochemical recurrence
    Prostate - PSMA agents medically necessary uses: PET/CT or PET/MRI with Ga-68 PSMA, flotufolastat F-18, or piflufolastat F-18 may be considered medically necessary for: (a) staging in diagnosed prostate cancer with NCCN unfavorable intermediate-, high-, or very-high-risk or with equivocal/oligometastatic conventional imaging; (b) suspected recurrence based on PSA after radical prostatectomy (PSA persistence or rise from undetectable) or after definitive radiotherapy (PSA rise above nadir); (c) imaging workup for progression in treated prostate cancer; (d) staging for patients who are candidates for lutetium Lu-177 vipivotide tetraxetan PSMA-directed therapy.NCCN risk categories and PSA-based recurrence conditions

    See Policy Guidelines for NCCN definitions and PSA specifics

    Prostate - other PSMA uses: Use of PSMA agents in known or suspected prostate cancer is experimental/investigational for all other indications including diagnosis, primary staging of very-low/low/favorable intermediate-risk disease, and evaluation of response to therapy.other indications
    Prostate - other PET uses: PET scanning for all other indications in known or suspected prostate cancer is experimental/investigational.other indications

    D. Renal Cell Carcinoma

    Renal cell carcinoma coverage statements

    Renal cell carcinoma: FDG-PET or FDG-PET/CT is considered experimental/investigational in all aspects of managing renal cancer.all indications

    E. Testicular Cancer

    Testicular cancer coverage statements

    Testicular cancer - seminoma residual mass: FDG-PET or FDG-PET/CT may be considered medically necessary for evaluation of residual mass following chemotherapy of stage IIB and III seminomas; scan should be completed no sooner than 6 weeks after chemotherapy.stage IIB or III seminoma; >=6 weeks post-chemotherapy
    Testicular cancer - other: Except as noted for seminoma residual mass, PET scanning is experimental/investigational for testicular cancer including initial staging, distinguishing viable tumor vs necrosis/fibrosis after treatment, and detection of recurrent disease.other indications

    F. Cancer Surveillance

    Cancer surveillance stance

    Surveillance exclusion: PET scanning is experimental/investigational when used as a surveillance tool: defined as scans performed more than 6 months after completion of cancer therapy (12 months for lymphoma) in individuals without objective signs or symptoms suggestive of recurrence.>6 months post-therapy (12 months for lymphoma)

    Covered and uncertain indications

    Coverage and appropriateness summarized by indication:

    Surveillance: PET scanning used as surveillance in asymptomatic individuals (performed >6 months after completion of cancer therapy, or >12 months for lymphoma) is considered experimental/investigational.>6 months (12 months lymphoma)

    See Policy Guidelines for definition of surveillance.

    PSMA PET for Prostate Cancer - Appropriate Uses: PSMA PET imaging is appropriate for individuals post-treatment with suspected persistence or recurrence when criteria are met (post-prostatectomy: failure of PSA to fall to undetectable OR previously undetectable PSA with subsequent detectable PSA increasing on ≥2 measurements; post-radiation: PSA rise ≥2 ng/mL above nadir OR positive DRE). PSMA PET may also be considered for increasing PSA after radiation even if <2 ng/mL in salvage candidates.PSA criteria as stated

    Not recommended for very low, low, or favorable intermediate NCCN risk groups or for suspected disease based only on elevated PSA/abnormal DRE without other indications.

    FDG-PET/CT for Bladder Cancer: FDG-PET/CT may be useful for pretreatment staging of muscle-invasive bladder cancer and for follow-up in selected/high-risk patients per NCCN and ACR statements; it is not the preferred modality and is recommended as 'may be useful' or 'may be appropriate' in selected scenarios.selected patients with >=cT2 / >=cT3 or high-risk features

    PET/CT should not be used to delineate upper urinary tract anatomy or in nonmuscle invasive bladder cancer.

    FDG-PET/CT for muscle-invasive bladder cancer

    Covered when ALL of the following are met (muscle-invasive bladder cancer staging/restaging):

    Bladder cancer - muscle invasive: FDG-PET/CT may be used for diagnosis, staging, and restaging of muscle-invasive bladder cancer based on pooled analyses and guidelines noting effectiveness for staging.

    ACR and NCCN support selective use in muscle-invasive disease

    PET/CT for penile cancer with suspected nodal disease

    Covered when ANY of the following are met (penile cancer):

    Suspected node-positive penile cancer: FDG-PET/CT may be used for lymph node staging and evaluation of distant metastases in individuals with suspected inguinal or pelvic node-positive penile cancer.

    Meta-analysis shows high pooled sensitivity and specificity vs histopathology; NCCN guidance supports use in suspected node-positive disease

    PET tracers for prostate cancer recurrence and management

    Covered when ALL of the following are met (prostate cancer - biochemical recurrence or suspected residual/recurrent disease):

    Prostate cancer biochemical recurrence: 11C-choline or 18F-fluciclovine PET/CT (or PET/MRI) may be used to detect biochemically recurrent small-volume disease when conventional imaging is negative or equivocal.

    Supported by systematic reviews, prospective trials, and guideline statements (ACR, SNMMI, NCCN)

    Bone assessment adjunct: 18F-sodium fluoride PET/CT or PET/MRI may be considered for further bone assessment.

    NCCN guidance

    Indications supported by evidence/guidelines

    Covered when supported by guideline or evidence for the indicated clinical scenario:

    Detection of biochemical recurrence: Use of 11C-choline or 18F-fluciclovine PET/CT or PET/MRI may be used for detection of biochemically recurrent small-volume disease in soft tissues and bone; PSMA-targeting PET agents may detect recurrence at lower PSA levels and are supported by FDA approvals and systematic review evidence.N/A

    NCCN and SNMMI cite these agents for biochemical recurrence

    Staging and restaging: Evidence supports use of 11C-choline and 18F-fluciclovine PET and PSMA PET for diagnosis, staging, and restaging of prostate cancer; PSMA PET shows higher sensitivity and may alter management plans.N/A

    Systematic reviews and prospective studies report detection rates and changes in management

    Not routine initial FDG-PET: FDG-PET should not be used routinely for initial assessment of prostate cancer due to limited evidence of clinical utility.N/A

    Guideline statement

    PSMA PET — medically necessary in selected prostate cancer scenarios

    Covered when evidence supports use in selected clinical scenarios

    PSMA PET covered uses: PSMA PET (68Ga-PSMA, piflufolastat-F18, flotufolastat-F18) is supported for staging, restaging, and surveillance of prostate cancer in selected individuals as informed by systematic reviews and prospective trials; guideline-concordant indications include newly diagnosed unfavorable intermediate/high/very-high-risk disease, detection of biochemical recurrence, and evaluation when conventional imaging is equivocal.

    Supported by NCCN and SNMMI recommendations and prospective trials (proPSMA, CONDOR, SPOTLIGHT, LIGHTHOUSE, Fendler et al).

    RCC — limited/conditional coverage

    FDG-PET/CT for renal cell carcinoma

    RCC uses: Evidence is limited and heterogeneous; pooled lesion-level detection rates suggest promise for PSMA-PET/CT in RCC, but current NCCN guidance states PET value in RCC remains to be determined and PET/PET-CT alone is not standardly used for diagnosis or routine follow-up; FDG-PET has limited supportive indications (eg, FH-deficient or SDHB-deficient RCC, bone-predominant disease) per NCCN.

    Larger prospective trials recommended.

    Testicular cancer — supported use for postchemotherapy seminoma residual masses

    PET/CT for testicular cancer

    Testicular cancer PET use: FDG-PET/CT is supported for evaluation of residual masses >3 cm after chemotherapy for seminoma (≥6 weeks posttreatment). PET is not recommended for nonseminoma patients and is not supported for surveillance.residual mass >3 cm; >=6 weeks post-chemotherapy

    NCCN guidance specifies surveillance if negative, resection/biopsy if positive, repeat PET in 6-8 weeks if indeterminate.

    Testicular Cancer - Seminoma

    Covered when evidence supports clinical utility:

    Seminoma post-chemotherapy residual mass: FDG-PET or FDG-PET/CT can be useful in evaluating residual masses following chemotherapy for seminoma.

    Based on AHRQ systematic review and NCCN guideline recommendations

    Testicular Cancer - Nonseminoma and Surveillance

    Not supported / not covered when evidence lacking:

    Nonseminoma: No evidence supporting the use of PET or PET/CT in nonseminoma individuals.

    Evidence does not support use

    Surveillance: The evidence does not support the use of FDG-PET and FDG-PET/CT for surveillance of testicular cancer.

    Surveillance refers to asymptomatic interval testing >6 months post-therapy

    The policy includes multiple explicit exclusions across genitourinary cancer types. PET/PET-CT is experimental/investigational and not covered for non–muscle-invasive bladder tumors (stage < cT2), for most indications in penile cancer other than suspected inguinal node–positive disease, for renal cell carcinoma in all aspects of management, and for most uses in testicular cancer except evaluation of postchemotherapy seminoma residual masses. Additionally, PET applications not supported by evidence include many prostate cancer uses outside the specified indications for choline, fluciclovine, and PSMA-targeting agents.

    The policy also states that PET used as a surveillance tool in asymptomatic individuals—defined as scans performed more than 6 months after completion of cancer therapy (or 12 months for lymphoma)—is considered experimental/investigational and not medically necessary.

    Per guideline and policy statements, PET/CT should not be used to delineate the anatomy of the upper urinary tract. In bladder cancer, PET/CT is specifically not recommended for nonmuscle invasive disease and is intended for selected use in muscle-invasive disease where conventional imaging is inconclusive.

    The NCCN guidance cited in the policy emphasizes FDG-PET/CT as a potentially useful adjunct for assessing regional or distant metastases in muscle-invasive bladder cancer but reiterates that PET/CT is not an anatomic study for upper urinary tract delineation.

    The policy explicitly states that use of FDG-PET/CT is not supported for nonmuscle invasive bladder cancer (stage < cT2) and that PET scanning for those bladder tumors is considered experimental/investigational.

    Section summaries and the Policy wording align: FDG-PET/CT is supported for staging/restaging of muscle-invasive bladder cancer in selected scenarios but not for nonmuscle-invasive disease.

    For penile cancer, the policy limits PET/CT utility to patients with suspected inguinal lymph node–positive disease. The document states that PET/CT is not supported for diagnosis, staging, restaging, or surveillance of node‑negative penile cancer, and that PET scanning is considered experimental/investigational for other penile cancer indications.

    Guideline and evidence summaries note that PET/CT may increase sensitivity for nodal disease in suspected node‑positive cases, but the evidence does not support PET use when nodes are clinically negative.

    The policy indicates that evidence does not support the use of 11C‑choline PET (and PET/CT) or 18F‑fluciclovine PET (and PET/CT) for surveillance of prostate cancer. While these agents may be medically necessary for evaluation of suspected or biochemically recurrent disease, their use for routine surveillance in asymptomatic individuals lacks supporting evidence and is considered not medically necessary.

    Choline and fluciclovine are described as appropriate for detection of recurrent small‑volume disease when conventional imaging is negative or equivocal, but explicitly not for surveillance purposes.

    The policy and cited evidence do not support use of PSMA PET for the initial diagnosis of prostate cancer. Systematic reviews and guideline summaries note that PSMA PET lacks sufficient evidence for primary diagnosis, and ASCO recommendations advise against PET/CT for staging early low‑risk prostate cancer.

    PSMA PET is, however, supported in selected staging and recurrence scenarios; the policy distinguishes those covered PSMA indications from unsupported initial diagnostic uses.

    For testicular cancer, the policy indicates that PET is not supported for surveillance in asymptomatic individuals. PET/PET‑CT is described as useful for evaluation of residual masses following chemotherapy for seminoma but not supported for routine surveillance imaging in asymptomatic patients.

    Surveillance use—imaging performed more than 6 months after completion of therapy (or 12 months for lymphoma) in asymptomatic individuals—is categorized as experimental/investigational and may be denied.

    While the policy includes numerous explicit exclusions within its coverage and not‑medically‑necessary sections, the reference listings and bibliographic entries themselves do not uniformly list standalone coverage exclusions. The policy text and section summaries (rather than the reference list) contain the explicit exclusion statements used to determine coverage stance.

    The references support the evidence base but do not replace the policy’s explicit exclusion language for specific indications.

    The policy requires that PET or PET/CT scans considered medically necessary are those in which the imaging results will influence treatment decisions. If results are unlikely to affect management, the scan is considered not medically necessary and may be denied.

    Providers should document the anticipated impact of PET findings on treatment planning when requesting authorization to align with the policy’s medical‑necessity requirement.

    The policy defines surveillance imaging as scans performed more than 6 months after completion of cancer therapy in asymptomatic individuals, and as more than 12 months for lymphoma. PET scanning used in this surveillance context is considered experimental/investigational and not medically necessary.

    This surveillance exclusion is distinct from imaging performed for suspected recurrence in symptomatic patients or when clinical/laboratory findings prompt targeted restaging.

    The policy again emphasizes that FDG‑PET/CT and related FDG‑based PET tracers are not supported for nonmuscle invasive bladder cancer and are not supported for management of node‑negative penile cancer. These uses are designated experimental/investigational and not covered.

    Those tracer‑specific exclusions are called out separately from broader modality or indication exclusions in the coverage statements and section summaries.

    The evidence summarized in the policy does not support surveillance imaging with 11C‑choline or 18F‑fluciclovine PET/PET‑CT. Although these tracers are appropriate for detecting recurrent prostate cancer in symptomatic or PSA‑rising individuals, their use for routine surveillance in asymptomatic patients is not supported by the available data.

    Policy language and the subsection summary explicitly state these tracer uses are not supported for surveillance.

    PSMA PET is not supported for initial diagnosis or primary staging in patients with very low, low, or favorable intermediate risk prostate cancer, and ASCO recommends against PET/CT for staging early low‑risk disease. The policy restricts PSMA PET to guideline‑concordant scenarios (eg, unfavorable intermediate/high/very‑high risk, biochemical recurrence, equivocal conventional imaging, or selection for PSMA‑targeted therapy).

    Use of PSMA agents outside those specified indications is considered experimental/investigational.

    The policy states that FDG‑PET and FDG‑PET/CT are not supported for surveillance of testicular cancer. While FDG‑PET/CT may be medically necessary to evaluate postchemotherapy residual masses in seminoma, routine surveillance imaging with FDG tracers in asymptomatic individuals is not supported.

    Surveillance requests in testicular cancer should therefore be evaluated against the policy’s surveillance exclusion criteria.

    Although the policy contains explicit not‑medically‑necessary and not‑covered statements within its main text and section summaries, the external reference listings themselves do not consistently contain separate, explicit 'not medically necessary' labels. The policy language—rather than the reference list—defines the actual coverage and exclusion determinations.

    Clinicians and billing staff should rely on the policy statements and section summaries for coverage decisions rather than expecting the reference list to contain exclusional language.

    Specific Covered Indications

    Bladder cancer staging/restaging

    Bladder cancer staging/restaging

    Bladder cancer staging/restaging: Muscle-invasive bladder cancer when CT or MRI are not indicated or are inconclusive for distant metastasis; FDG-PET/CT may be considered medically necessary for staging and restaging in selected patients.stage >= cT2

    Supported by systematic review/meta-analysis and ACR/NCCN guidance

    Penile cancer staging/restaging

    Penile cancer staging/restaging

    Penile cancer staging/restaging: Suspected inguinal lymph node–positive disease where PET/CT may be considered to evaluate nodal and distant metastases.inguinal lymph node positive suspected

    Supported by meta-analysis and NCCN guidance

    Prostate cancer staging/restaging and recurrence workup with PSMA agents

    Prostate cancer staging/restaging and recurrence workup with PSMA agents

    Prostate PSMA staging/recurrence: PSMA PET/CT or PET/MRI indicated for staging in unfavorable intermediate-/high-/very-high-risk disease, for suspected recurrence based on PSA criteria after prostatectomy or radiotherapy, for workup of progression in treated disease, and for selecting patients for PSMA-directed therapy.NCCN risk categories; PSA-based recurrence conditions

    See Policy Guidelines for detailed PSA/DRE criteria

    Testicular seminoma residual mass evaluation

    Testicular seminoma residual mass evaluation

    Seminoma residual mass evaluation: Residual mass after chemotherapy for stage IIB or III seminoma; PET/CT performed no sooner than 6 weeks post-chemotherapy; management guided by PET result (surveillance if negative; resection/biopsy if positive; repeat in 6–8 weeks if indeterminate).residual mass >3 cm; >=6 weeks post-chemo

    NCCN guidance

    FDG-PET/CT for bladder cancer staging and follow-up

    FDG-PET/CT for bladder cancer staging and follow-up

    FDG-PET/CT bladder staging/follow-up: May be beneficial in selected patients with muscle-invasive disease (>=cT2) and may change management in >=cT3 disease; may be performed in follow-up of high-risk patients or when metastasis suspected.>=cT2/>=cT3 as noted

    ACR/NCCN categorize as may be useful/appropriate (category 2B)

    PSMA PET for prostate cancer staging and recurrence evaluation

    PSMA PET for prostate cancer staging and recurrence evaluation

    PSMA PET staging/recurrence: Appropriate for unfavorable intermediate, high, and very-high NCCN risk groups for staging, and appropriate for post-treatment workup of suspected persistence/recurrence per PSA/DRE criteria.NCCN risk group definitions and PSA/DRE criteria

    Not recommended for very low, low, or favorable intermediate risk groups

    Bladder cancer staging and follow-up (selected high-risk/muscle-invasive cases)

    Bladder cancer staging and follow-up (selected high-risk/muscle-invasive cases)

    Selected muscle-invasive bladder cases: FDG-PET/CT may be beneficial for staging in selected patients with >=cT2 disease and may change management in >=cT3 disease; may be considered for chest, abdominal/pelvic, or bone assessment in symptomatic or high-risk patients.

    NCCN category 2B; avoid use for nonmuscle invasive disease or for upper urinary tract delineation

    Penile cancer with suspected nodal disease

    Penile cancer with suspected nodal disease

    Penile cancer suspected nodal disease: PET/CT may be considered for cross-sectional imaging for staging or treatment response assessment in suspected inguinal node-positive disease and to evaluate enlarged pelvic nodes when biopsy is not feasible.

    Supported by meta-analysis and NCCN

    Prostate cancer biochemical recurrence or suspected residual/recurrent disease

    Prostate cancer biochemical recurrence or suspected residual/recurrent disease

    Biochemical recurrence indication: 11C-choline or 18F-fluciclovine PET/CT is appropriate for patients with clinical concern for residual or recurrent disease following radical prostatectomy, nonsurgical treatments, or systemic therapy, especially when conventional imaging is negative or equivocal.

    ACR, SNMMI, NCCN support

    Detection of biochemical recurrence

    Detection of biochemical recurrence

    Detection of biochemical recurrence: PET/CT or PET/MRI with 11C-choline, 18F-fluciclovine, or PSMA-targeting agents may be used to detect small-volume local and distant recurrence; use guided by PSA and clinical context per guidelines.Relevant PSA and clinical context per guidelines

    Supported by NCCN and SNMMI and systematic reviews

    Staging and detection of clinically significant prostate cancer

    Staging and detection of clinically significant prostate cancer

    Staging and detection of clinically significant prostate cancer: PSMA PET and PSMA PET/MRI have diagnostic accuracy similar to MRI for clinically significant prostate cancer and may assist in lymph node staging; use in newly diagnosed intermediate/high-risk patients is supported by evidence but not for routine initial diagnosis in low-risk groups.Use in newly diagnosed intermediate/high risk patients as supported by evidence

    Systematic reviews report pooled sensitivity/specificity

    PSMA PET indications per NCCN/SNMMI

    PSMA PET indications per NCCN/SNMMI

    Appropriate PSMA PET indications: Newly diagnosed unfavorable intermediate-, high-, or very-high-risk prostate cancer; biochemical recurrence after definitive therapy; equivocal conventional imaging; evaluation of progression in treated disease; selection of candidates for PSMA-targeted theranostic therapy (eg, Pluvicto).

    Based on NCCN and SNMMI recommendations and trial evidence

    Testicular cancer residual mass evaluation

    Testicular cancer residual mass evaluation

    Postchemotherapy seminoma residual mass: FDG-PET/CT to evaluate residual masses >3 cm at ≥6 weeks after chemotherapy; negative PET→surveillance; positive PET→resection/biopsy; indeterminate→repeat PET in 6–8 weeks.residual mass >3 cm

    NCCN testicular cancer guideline

    Evaluation of residual mass after chemotherapy in seminoma

    Evaluation of residual mass after chemotherapy in seminoma

    Restaging/evaluation of residual mass in seminoma: FDG-PET/CT is useful for evaluating residual masses after chemotherapy in seminoma.

    AHRQ systematic review support

    Procedure and Radiopharmaceutical Codes

    FDA-approved radiopharmaceuticals for genitourinary PETmixed
    C-11Carbon-11 choline (radiopharmaceutical) — FDA indication: suspected prostate cancer recurrence based on elevated PSA after therapy and noninformative bone scan, CT, or MRI.
    F-18 FDGFluorine-18 fluorodeoxyglucose (FDG) — FDA indication: suspected or existing diagnosis of cancer, all types.
    F-18 fluciclovineFluciclovine (Axumin) — FDA indication: suspected prostate cancer recurrence based on elevated PSA after treatment.
    Ga-68 PSMA-11Gallium-68 PSMA-11 — FDA indication: PSMA-positive lesions in men with prostate cancer with suspected metastasis or suspected recurrence; multiple preparation kits (Illuccix, Locametz, Gozellix) noted.
    piflufolastat F-18Piflufolastat F-18 (Pylarify) — FDA indication: PSMA-positive lesions in men with suspected metastasis or recurrence.
    flotufolastat F-18Flotufolastat F-18 (Posluma) — FDA indication: PSMA-positive lesions in men with suspected metastasis or recurrence.
    Referenced PET modalities/tracersmixed
    FDG-PET/CTFluorodeoxyglucose PET/CT imaging (referenced for bladder, penile, prostate sections).
    11C-choline PET/CTCarbon-11 choline PET/CT (prostate and recurrence contexts).
    18F-fluciclovine PET/CTFluciclovine PET/CT for prostate cancer recurrence and management guidance.
    18F-sodium fluoride PET/CT18F-sodium fluoride PET/CT for bone assessment adjunct in prostate cancer.
    Referenced PET radiotracersmixed
    68Ga-PSMAPSMA-targeting PET radiotracer (example agent).
    piflufolastat-F18FDA-approved PSMA-targeting PET radiotracer (piflufolastat F-18).
    flotufolastat-F18FDA-approved PSMA-targeting PET radiotracer (flotufolastat F-18).
    11C-cholineCarbon-11 choline PET radiotracer.
    18F-fluciclovineFluciclovine PET radiotracer (Axumin).
    18F-sodium fluorideBone-targeting PET radiotracer for skeletal assessment.
    FDGFluorodeoxyglucose (FDG) PET radiotracer (general oncology use).
    Covered CPT/HCPCS Imaging CodesCPTCovered
    78811Positron emission tomography (PET) imaging; limited area (e.g. Chest, head/neck).
    78812Positron emission tomography (PET) imaging; skull base to mid-thigh.
    78813Positron emission tomography (PET) imaging; whole body.
    78814Tumor imaging, PET with concurrently acquired CT; limited area (e.g. chest, head/neck).
    78815Tumor imaging, PET with concurrently acquired CT; skull base to mid-thigh.
    78816Tumor imaging, PET with concurrently acquired CT; whole body.
    HCPCS Radiopharmaceutical CodesHCPCSCovered
    A9515Choline C-11 injection, diagnostic, per study dose up to 20 millicuries.
    A9552Fluorodeoxyglucose F-18 (FDG), diagnostic, per study dose, up to 45 millicuries.
    A9588Fluciclovine F-18, diagnostic, 1 millicurie.
    A9593Gallium Ga-68 PSMA-11, diagnostic (UCSF), 1 millicurie.
    A9594Gallium Ga-68 PSMA-11, diagnostic (UCLA), 1 millicurie.
    A9595Piflufolastat F-18, diagnostic, 1 millicurie.
    A9596Gallium Ga-68 gozetotide, diagnostic (Illuccix), 1 millicurie.
    A9597Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified.
    A9598Positron emission tomography radiopharmaceutical, diagnostic, for non-tumor identification, not otherwise classified.
    A9608Flotufolastat F-18, diagnostic, 1 millicurie.
    1–10 of 14
    1/2
    Post-treatment surveillance timing — definition and timeframe
    DefinitionSurveillance: imaging performed more than 6 months after completion of cancer therapy (12 months for lymphoma) in asymptomatic individuals.
    Policy triggerA scan is considered surveillance if performed >6 months post-therapy (≥12 months for lymphoma).
    ImplicationPET scanning used as surveillance is considered experimental/investigational and may be denied/not medically necessary.
    PSA velocity / PSA level — PSA velocity >2 ng/mL/yr associated with higher pooled sensitivity
    PSA velocity thresholdPSA velocity >2 ng/mL per year is associated with higher pooled sensitivity for radiolabeled choline PET/CT (meta-analysis reporting maximum pooled sensitivity 77%).
    Lower PSA velocityPooled sensitivity was lower for individuals with PSA velocity <2 ng/mL per year or short PSA doubling time (≤6 months).
    ContextFindings come from a meta-analysis of 14 studies (N=1667) assessing choline PET/CT for restaging prostate cancer.
    Median pre-imaging PSA (diagnostic study) — median 8.0 ng/mL
    Median pre-imaging PSAMedian pre-imaging PSA was 8.0 ng/mL (range 5.6 to 18 ng/mL) in diagnostic studies of PSMA PET for suspected prostate cancer.
    Study populationsFive studies reporting 497 individuals were included; some studies were biopsy-naïve while others had prior negative biopsies.
    PrevalencePrevalence of clinically significant prostate cancer in these cohorts was 59% (range 32% to 75%).
    PSA range in systematic reviews — ranges and medians reported
    Mazrani review rangeMazrani et al (2022): mean PSA not reported; reported range for participants with biochemical recurrence 0.2 to 14.9 ng/mL.
    Pozdnyakov mediansPozdnyakov et al (2022): median PSA 7.6 ng/mL at diagnosis and 1.3 ng/mL at time of PET imaging.
    Population contextSystematic reviews included prospective and retrospective studies of individuals with biochemical prostate cancer recurrence across varied PSA levels.
    PSA thresholds and detection rates (CONDOR) — detection rates by PSA strata
    Detection rate at low PSADetection rate in CONDOR: 36.2% for PSA <0.5 ng/mL.
    Detection rate at high PSADetection rate in CONDOR: 96.7% for PSA ≥5 ng/mL.
    Overall performance metricCONDOR reported correct localization rate (patient-level PPV/anatomic colocalization) of ~85–87% and a management change in 63.9% of evaluable individuals.
    Surveillance definition — use of PET to detect disease in asymptomatic individuals at various intervals
    Surveillance (policy) definitionUse of PET to detect disease in asymptomatic individuals at various intervals after treatment — distinct from imaging symptomatic individuals for suspected recurrence.
    Timing clarificationSurveillance imaging is completed ≥6 months after completion of treatment (≥12 months for lymphoma).
    Coding noteSurveillance described in coding refers specifically to asymptomatic interval testing and differs from restaging for suspected recurrence.

    Prior Authorization, Documentation, and Ordering Guidance

    Prior Authorization

    Prior authorization expectation

    Prior authorization is implied for PET/PET‑CT use under this payer policy; providers should follow usual payer prior‑auth processes and check member benefits. The policy notes that all statements apply to PET and PET/CT scans and that prior authorization expectations are implied by payer applicability.

    • Prior authorization is implied by payer policy applicability and usual prior‑auth processes.
    • Verify member contract benefits at time of service; inclusion of codes does not guarantee coverage.
    Prior Authorization

    Prior authorization for PET in genitourinary cancer

    Request prior authorization when PET is ordered for genitourinary cancers and ensure the indication aligns with NCCN/SNMMI guidance and the policy's risk‑group recommendations (for example, PSMA PET in specified prostate risk groups and FDG‑PET/CT in selected bladder cancer scenarios).

    • Prior authorization should reflect appropriate use per NCCN and SNMMI recommendations and the policy's risk‑group guidance.
    • Confirm clinical scenario and guideline concordance in the authorization request.
    Prior Authorization

    Prior authorization for oncologic PET/CT

    Obtain prior authorization when PET/CT is used to evaluate staging or suspected recurrence for bladder, penile, or prostate cancer and include indication‑specific rationale and prior conventional imaging results in the request.

    • Authorization should be requested for PET/CT used for staging or recurrence assessment.
    • Provide clinical rationale and prior imaging (CT/MRI/bone scan) results when available.
    Prior Authorization

    Prior authorization guided by guideline indications

    Prior authorization decisions should be guided by guideline‑supported indications for specific radiotracers (PSMA‑targeting agents, 11C‑choline, 18F‑fluciclovine) used for detection of biochemical recurrence and staging per professional guidance and evidence summaries.

    • Coverage decisions should reflect guideline‑supported uses and available evidence for the chosen tracer.
    • Include PSA metrics or prior imaging as applicable when seeking authorization for recurrence imaging.
    Prior Authorization

    Prior authorization for guideline‑concordant PSMA PET

    When requesting authorization for PSMA PET, confirm that the clinical scenario matches NCCN/SNMMI recommended situations (eg, unfavorable intermediate/high/very‑high risk staging, biochemical recurrence, equivocal conventional imaging, or selection for PSMA‑directed therapy).

    • Prior authorization should verify the indication aligns with guideline‑recommended scenarios.
    • Document NCCN/SNMMI concordant risk group or recurrence criteria in the request.
    Billing Rule

    Procedure and radiopharmaceutical codes subject to policy

    Include applicable PET procedure and radiopharmaceutical codes in authorization/claims, but recognize the codes are listed for informational purposes only and coverage is subject to the policy's medical necessity criteria and the member's contract.

    • Listed CPT/HCPCS codes are informational and are medically necessary only if performed according to policy criteria.
    • Verify member contract benefits; codes alone do not guarantee coverage.
    Prior Authorization

    Prior authorization not specified in references

    Reference sources provided do not specify distinct prior authorization processes; providers must follow local payer rules and submit clinical documentation to support medical necessity per this policy.

    • No specific prior‑auth procedures are described in the reference listings.
    • Follow payer’s prior authorization workflows and supply the documentation required by this policy.
    Step Therapy

    Imaging sequencing considerations

    When conventional imaging (CT/MRI/bone scan) is available and not equivocal, PSMA PET may be used per NCCN but conventional imaging is not always required as a prerequisite; authorization may be based on guideline rationale or discordant/equivocal prior imaging.

    • NCCN notes PSMA PET is more accurate and conventional imaging is not a necessary prerequisite.
    • If conventional imaging is equivocal or discordant, document that in authorization requests.
    Step Therapy

    Prefer conventional imaging before novel PET tracers

    Prefer conventional cross‑sectional imaging (CT or MRI) and bone scintigraphy as standard initial imaging for many prostate cancer scenarios; consider novel PET tracers when conventional imaging is negative, equivocal, or when guideline indications support PET.

    • CT/MRI and bone scan remain standard for post‑treatment workup per AUA guidelines.
    • Novel PET tracers may offer greater sensitivity but are often secondary to conventional imaging unless guidelines indicate otherwise.
    Note

    Evidence supports 11C‑choline and 18F‑fluciclovine (diagnosis/staging/restaging)

    Evidence supports use of 11C‑choline and 18F‑fluciclovine PET/PET‑CT for diagnosis, staging, and restaging of prostate cancer but not for surveillance; authorization and documentation should reflect these evidence‑supported uses.

    • 11C‑choline and 18F‑fluciclovine are supported for detection of biochemically recurrent small‑volume disease when conventional imaging is negative or equivocal.
    • These tracers are not supported for surveillance imaging.
    Step Therapy

    Conventional imaging not required prior to PSMA PET in select cases

    NCCN indicates that PSMA PET can be an alternative to conventional imaging and that conventional imaging is not required prior to PSMA PET in certain staging scenarios; document when PSMA PET is being used as an alternative per guideline recommendations.

    • NCCN states PSMA PET/CT or PET/MRI can serve as an equally effective frontline imaging tool and conventional imaging is not always necessary before PSMA PET.
    • When used as the alternative, document guideline‑concordant rationale in authorization requests.
    Documentation Required

    Must influence treatment decisions

    Documentation must show that PET results will influence treatment decisions; the policy specifies PET/PET‑CT are considered medically necessary only when the scan results would affect management.

    • If PET results will not influence treatment decisions, the scan is considered not medically necessary and may be denied.
    • Include intended management changes or how imaging will alter care in the authorization documentation.
    Documentation Required

    PSMA PET documentation (PSA and clinical criteria)

    For PSMA PET requests, include clinical details such as rising PSA with the policy‑specified criteria (post‑prostatectomy failure to fall to undetectable or rising on ≥2 measurements; post‑radiation PSA rise ≥2 ng/mL above nadir or positive DRE) to support medical necessity.

    • Document PSA trends and whether criteria for post‑prostatectomy or post‑radiation recurrence are met.
    • Provide prior PSA values and any relevant DRE findings.
    Documentation Required

    Clinical indication and prior imaging

    When requesting PET/CT, specify the cancer type and clinical scenario (eg, muscle‑invasive bladder cancer staging, suspected node‑positive penile cancer, biochemical recurrence of prostate cancer) and include prior standard imaging results when PET is being requested because of inconclusive or equivocal conventional imaging.

    • State cancer type and explicit clinical indication in documentation.
    • Attach prior CT/MRI/bone scan results if PET is sought due to negative or equivocal conventional imaging.
    Documentation Required

    PSMA PET to select Pluvicto candidates

    PSMA PET should be used to identify PSMA‑positive disease when selecting candidates for 177Lu‑vipivotide tetraxetan (Pluvicto); document PSMA‑positivity when PSMA‑directed therapy is being considered.

    • PSMA PET is recommended to select mCRPC patients for Pluvicto by identifying PSMA‑positive lesions.
    • Locametz (68Ga) was FDA‑approved as a theranostic in conjunction with Pluvicto; document PSMA imaging findings when therapy selection is intended.
    Billing Rule

    Member contract and medical necessity

    Inclusion of procedure, diagnosis, or device codes in the coding list does not guarantee member coverage; providers must verify the member's contract benefits at time of service and ensure the requested procedure meets the policy's medical‑necessity criteria.

    • Verify member contract benefits; codes listed are informational only.
    • Claims may be denied if the procedure is not consistent with the Policy section.
    Note

    No authorization/denial instructions in references

    Authorization or denial instructions are not provided in the cited reference listings; providers should follow payer‑specific prior authorization processes and submit the clinical documentation required by this policy.

    • No explicit authorization/denial instructions are included in reference sections.
    • Follow local payer prior‑auth requirements and provide policy‑relevant clinical documentation.
    Denial Risk

    Surveillance imaging denial trigger

    Surveillance PET scans performed in asymptomatic individuals more than 6 months after completion of therapy (12 months for lymphoma) are considered experimental/investigational and may be denied; do not request PET for routine surveillance beyond these timeframes without clear clinical signs.

    • Surveillance defined as >6 months post‑therapy (12 months for lymphoma).
    • PET for surveillance in asymptomatic patients may be denied as not medically necessary.
    Denial Risk

    FDG‑PET/CT for nonmuscle‑invasive bladder cancer (denial risk)

    Requests for FDG‑PET/CT for non‑muscle‑invasive bladder cancer are not supported by the evidence and may be denied; do not authorize FDG‑PET/CT for stage < cT2 bladder tumors.

    • Evidence does not support FDG‑PET/CT for nonmuscle invasive bladder cancer.
    • Policy states PET should not be used to delineate upper urinary tract anatomy or in nonmuscle invasive bladder cancer.
    Denial Risk

    Avoid routine FDG‑PET for initial prostate assessment

    Do not order FDG‑PET routinely for initial assessment of prostate cancer; the policy and guidelines state FDG‑PET should not be used routinely for initial prostate cancer evaluation because of limited clinical utility.

    • NCCN indicates FDG‑PET should not be used routinely for initial assessment.
    • Reserve FDG‑PET for select, evidence‑supported scenarios.
    Denial Risk

    Do not use PSMA PET for initial diagnosis outside guidelines

    PSMA PET is not supported for initial diagnosis of prostate cancer outside guideline‑recommended circumstances; inappropriate ordering for initial diagnosis or for low‑risk patients risks denial.

    • Systematic reviews and NCCN guidance do not support PSMA PET for initial diagnosis.
    • SNMMI and NCCN recommend against imaging in very low/low/favorable intermediate risk groups.
    Billing Rule

    Medical necessity tied to policy

    Ensure documentation demonstrates the procedure meets the Policy section criteria; procedures and codes in the coding list are medically necessary only if performed according to policy — claims inconsistent with policy may be denied.

    • Codes are medically necessary only when the procedure aligns with Policy criteria.
    • Claims may be denied if the service is not consistent with policy.
    Documentation Required

    Evidence of impact on management required

    When ordering PSMA PET, include documentation showing how imaging results will influence management (eg, guide salvage local therapy, alter systemic therapy, or determine candidacy for PSMA‑directed treatment); the policy requires PET results to influence treatment decisions for medical necessity.

    • Policy states PET results must influence treatment decisions to be medically necessary.
    • Document intended management changes or decision points influenced by PET results.
    Documentation Required

    PSMA PET documentation and clinical details

    For PSMA PET requests include clinical indication, prior imaging, PSA metrics, and any trial‑protocol specifics when relevant (eg, imaging windows used in SPOTLIGHT/LIGHTHOUSE) to support interpretation and medical necessity.

    • Document clinical indication and prior imaging results.
    • If applicable, note protocol imaging windows (eg, 50–70 minutes post‑injection) used in prospective trials to support imaging technique.
    Note

    Imaging Protocol and Contrast Considerations

    Note
    Note
    Note
    Note

    Uses Considered Experimental/Investigational or Not Covered

    The policy’s NOT COVERED section enumerates uses considered experimental/investigational and therefore not covered. These include PET/PET‑CT for non–muscle‑invasive bladder tumors; most penile cancer indications except suspected inguinal node‑positive disease; many prostate cancer indications outside the specified choline/fluciclovine/PSMA uses; all renal cell carcinoma applications; most testicular cancer uses except seminoma residual mass evaluation; and PET as surveillance (>6 months post‑therapy or ≥12 months for lymphoma) in asymptomatic individuals.

    These exclusions drive prior authorization and denial decisions when PET is requested for the listed not‑covered indications.

    The policy explicitly lists PET surveillance scans in asymptomatic patients performed more than 6 months after completion of therapy (or ≥12 months for lymphoma) as not covered. It also identifies PET/CT requests to delineate upper urinary tract anatomy as not covered and not an appropriate use of PET/CT.

    These not‑covered items are anchored to the policy’s surveillance definition and to guideline language that PET/CT is not an anatomic delineation modality for the upper urinary tract.

    Multiple entries in the policy’s not‑covered list specify that FDG‑PET/CT for nonmuscle invasive bladder cancer is not covered. The subsection summaries and policy statements consistently articulate that FDG‑PET/CT is supported only for selected muscle‑invasive bladder cancer indications and not for nonmuscle‑invasive disease.

    Requests for FDG‑PET/CT for nonmuscle invasive bladder tumors may be denied per the policy.

    The policy repeats that FDG‑PET/CT for nonmuscle invasive bladder cancer is considered experimental/investigational and not covered. This exclusion appears in multiple sections and summaries to avoid misinterpretation of the limited indications for bladder PET.

    Coverage for bladder cancer is thus restricted to staging/restaging of muscle‑invasive disease in selected clinical contexts.

    FDG‑PET/CT for nonmuscle invasive bladder cancer is consistently listed as not covered and experimental/investigational in the policy. The policy language stresses appropriate use is limited to muscle‑invasive disease when conventional imaging is inconclusive.

    Billing and authorization staff should apply this exclusion when evaluating claims or prior‑authorization requests for bladder PET in nonmuscle invasive settings.

    The policy’s not‑covered determinations again identify FDG‑PET/CT for nonmuscle invasive bladder cancer as experimental/investigational and not covered. Multiple not‑covered entries repeat this finding to ensure clarity across sections.

    Requests for PET/CT in nonmuscle invasive bladder cancer should be evaluated against the policy’s explicit exclusion language.

    A further not‑covered entry reiterates that FDG‑PET/CT is not supported for nonmuscle invasive bladder cancer. The repetition across not‑covered listings highlights that PET is reserved for muscle‑invasive disease when indicated.

    This repeated exclusion supports consistent application of the policy across prior authorization and claims adjudication.

    Key Definitions and Terms

    Staging — definition and use of PET for determining extent at diagnosis
    Staging definitionStaging: use of PET to determine the extent of cancer at the time of diagnosis before treatment (to assess localization vs metastasis).
    PurposeStaging imaging is generally performed to determine whether the cancer is localized and to guide initial management.
    Policy applicationPET for staging is addressed in tumor-specific policy statements and may be medically necessary when criteria are met.
    Surveillance — imaging performed >6 months after completion of therapy (12 months for lymphoma)
    Surveillance timeframeSurveillance defined as imaging performed >6 months after completion of therapy (≥12 months for lymphoma).
    Asymptomatic populationApplies to asymptomatic individuals without objective signs or symptoms suggestive of recurrence.
    Policy stancePET used as surveillance is considered experimental/investigational and may be denied/not medically necessary.
    Surveillance — imaging in asymptomatic patients ≥6 months (≥12 months for lymphoma) after treatment completion
    Surveillance definitionImaging in asymptomatic patients completed ≥6 months (≥12 months for lymphoma) after completion of treatment is considered surveillance.
    Distinct from restagingSurveillance differs from restaging for suspected recurrence, which is performed when signs or symptoms suggest disease return.
    Policy effectSurveillance imaging is experimental/investigational per the policy guidelines and exclusions.
    Restaging — imaging after treatment when recurrence suspected or to determine extent post-treatment
    Restaging definitionRestaging: imaging after treatment when recurrence is suspected based on signs/symptoms, or to determine extent after completion of therapy.
    Two scenariosIncludes evaluation for suspected recurrence (symptomatic) and assessment of extent post-treatment (as part of treatment evaluation).
    Distinction from surveillanceRestaging for suspected recurrence is not surveillance and is addressed as a tumor-specific indication in the policy statements.
    Biochemical recurrence (prostate cancer) — rising PSA after definitive primary therapy
    Biochemical recurrence definitionRising PSA after definitive primary therapy (radical prostatectomy or radiotherapy) indicating possible recurrent disease prompting imaging evaluation.
    Imaging agentsPET tracers such as 11C-choline or 18F-fluciclovine may be used to localize recurrence when conventional imaging is negative or equivocal.
    Guideline supportACR and SNMMI appropriate use criteria support PET use in biochemical recurrence scenarios when standard imaging is uninformative.
    PSMA PET — PSMA-targeting radiotracers and examples
    PSMA PET definitionPSMA PET: positron emission tomography using prostate-specific membrane antigen–targeting radiotracers (e.g., 68Ga-PSMA, piflufolastat-F18, flotufolastat-F18).
    ExamplesExamples of PSMA-targeting agents include 68Ga-PSMA-11, piflufolastat F-18, and flotufolastat F-18 as cited in the document.
    Clinical usesUsed for staging, detection of biochemical recurrence, and selection of candidates for PSMA-directed therapy when guideline criteria are met.
    Correct localization rate — CONDOR trial metric definition
    Correct localization rate (CONDOR)Defined as the percentage of individuals with at least one PET-identified lesion that corresponded 1:1 with the composite standard of truth (patient-level PPV plus anatomic lesion colocalization).
    PurposeUsed as the primary endpoint in CONDOR to represent patient-level PPV when specificity is impractical to measure in high-prevalence recurrent disease.
    Operational noteCorrect localization rate reflects concordance between central readers’ PET findings and histopathology/imaging/therapy response reference standards.
    Use of PET scanning to detect disease in asymptomatic individuals at various intervals (surveillance definition)
    Surveillance (reiterated)Use of PET scanning to detect disease in asymptomatic individuals at various intervals after treatment — distinct from imaging symptomatic individuals for suspected recurrence.
    Policy implicationSuch surveillance imaging is considered experimental/investigational and not medically necessary per policy language.
    Coding/categorizationPolicy coding clarifies surveillance refers to asymptomatic interval testing and is treated separately from tumor-specific restaging indications.
    PSMA PET imaging and diagnostic accuracy studies cited — definition/context
    PSMA PET contextPSMA PET imaging and diagnostic accuracy studies include systematic reviews and prospective trials (eg, diagnostic accuracy of 68Ga-PSMA-11, proPSMA, CONDOR, SPOTLIGHT, LIGHTHOUSE) providing pooled sensitivity/specificity and detection rates.
    Study typesEvidence cited includes systematic reviews, meta-analyses, and prospective multicenter phase 3 trials assessing detection rates, localization, and impact on management.
    Clinical relevanceThese studies inform guideline recommendations and policy statements regarding PSMA PET use for staging, restaging, and selecting candidates for PSMA-directed therapy.

    Prior Authorization Expectations

    Note
    Note
    Note
    Note
    Note
    Note

    Background — PET/PET-CT and Radiotracers

    Background: Positron emission tomography (PET) is a nuclear imaging technique that uses positron‑emitting radiotracers to image metabolic or molecular processes. Tracer selection depends on tumor type and clinical question; for example, FDG is commonly used for many tumor types, whereas PSMA‑targeting agents, choline, and fluciclovine are used for prostate cancer applications. PET may be performed with or without CT or MRI fusion (PET/CT or PET/MRI) to provide anatomic localization.

    The policy applies these principles by matching tracer choice and PET modality to the specific genitourinary cancer indications supported by evidence and guideline recommendations.

    Frequency Limits and Related Notes

    frequency limits placeholder (no explicit data in inventory)
    Frequency limits noteNo explicit frequency limits are specified in the policy excerpt provided; frequency limits placeholder present in inventory.
    Coding sectionThe coding/frequency limits section contains no modality-specific periodicity limits in the provided reference chunks.
    RecommendationRefer to payer-specific prior authorization and member contract for any local frequency restrictions.

    Rationale, Evidence Summary, and References

    References supporting use of PET/PSMA PET in oncologic staging and restaging

    References supporting use of PET/PSMA PET in oncologic staging and restaging

    Referenced clinical indications: Citations include studies and guidelines related to PSMA PET for prostate cancer staging/restaging and PET for various oncologic conditions (renal cell carcinoma, seminoma, testicular cancer, etc.).

    See Reference list in Policy